{"title": "REVIEW OF EVIDENCE: HETEROLOGOUS AND HOMOLOGOUS BOOSTING FOR SINOVAC PRIMARY SERIES RECIPIENTS", "author": "Institute", "url": "https://www.slideshare.net/ICRInstituteForClini/review-of-evidence-heterologous-and-homologous-boosting-for-sinovac-primary-series-recipients", "hostname": "slideshare.net", "description": "With reference to the media statement dated 9 February 2022 (link) by Pharmaniaga Berhad regarding the lower effectiveness of heterologous boosting for Sinovac...", "sitename": "SlideShare", "date": "2021-09-22", "cleaned_text": "Global & Malaysia data has consistently shown that after 2 doses of Sinovac, a Pfizer/AstraZeneca booster is more effective than a 3rd dose of Sinovac, especially Omicron. And despite a third dose of Sinovac, levels of 'neutralizing' antibodies, tend to remain low. "}